Sinonasal metastasis is the metastatic spread of distant primary malignancies to the paranasal sinuses and nasal cavity through hematogenous, lymphatic, or direct extension pathways. It is a rare condition and constitutes 1-3% of all sinonasal malignancies. The most common primary tumor sources are renal cell carcinoma (RCC — especially clear cell type, hypervascular), breast carcinoma, lung carcinoma, prostate carcinoma, and melanoma. RCC metastases may present with intense enhancement and spontaneous massive epistaxis due to their hypervascular nature. Sinonasal metastases are generally a component of widespread metastatic disease and isolated sinonasal metastasis is rare. Aggressive bone destruction, rapid growth, and known primary malignancy history should raise suspicion for the diagnosis.
Age Range
40-80
Peak Age
60
Gender
Equal
Prevalence
Rare
Sinonasal metastases develop through three main pathways: (1) Hematogenous spread — the most common route, especially for RCC, breast, and lung carcinomas. The rich vascular network of paranasal sinuses and Batson's vertebral venous plexus system (valveless venous connections) provides the metastatic pathway. (2) Lymphatic spread — less common, retrograde spread through cervical lymph nodes. (3) Direct extension — invasion from adjacent structures (nasopharynx, orbit, skull base). The hypervascular nature of RCC metastases reflects the tumor's intense angiogenesis — VEGF (vascular endothelial growth factor) expression is high and creates numerous thin-walled, wide-caliber new vessels. These vessels show very intense enhancement and bleeding control is difficult — massive epistaxis may be the main clinical presentation. Osteolytic bone destruction reflects osteoclast activation through RANKL and metalloproteinases secreted by tumor cells. Prostate metastases may be osteoblastic (high-density sclerotic bone formation).
The most important diagnostic indicator of sinonasal metastasis is the presence of a sinonasal mass showing aggressive bone destruction in a patient with known primary malignancy history. Destruction is usually osteolytic type, rapidly progressive, and similar to primary sinonasal carcinomas but known malignancy history brings metastasis to the forefront. Intense enhancement and epistaxis are additional diagnostic clues in RCC metastasis.
On contrast-enhanced CT, sinonasal metastasis appears as a combination of an enhancing soft tissue mass with aggressive bone destruction. Enhancement degree varies with primary tumor: RCC metastases show very intense and homogeneous enhancement (hypervascular — may mimic JNA), lung and breast metastases show moderate-prominent heterogeneous enhancement, prostate metastases may show lower enhancement. Bone destruction is usually aggressive osteolytic type — cortical bone destruction, permeative pattern, irregular borders. Prostate metastases may be osteoblastic (high-density sclerotic bone). The mass may extend to adjacent sinuses, orbit, nasal cavity, and skull base.
Report Sentence
A soft tissue mass with __ enhancement accompanied by aggressive bone destruction in the __ sinus is observed; metastasis should be primarily considered in the context of known primary malignancy.
On bone window CT, sinonasal metastasis shows aggressive bone destruction — this finding is distinctly different from benign lesions (osteoma, fibrous dysplasia, ossifying fibroma) and some primary malignancies' bone patterns (lymphoma — bone preservation). In osteolytic pattern, cortical bone is completely destroyed, trabecular bone is permeatively infiltrated, and sinus walls become unrecognizable. Destruction is irregular-bordered with minimal reactive bone formation (sclerosis). In prostate-origin metastases, osteoblastic pattern — dense sclerosis with new bone formation — may be seen. Breast metastases may show mixed osteolytic-osteoblastic pattern. Orbital floor, lamina papyracea, cribriform plate, and sphenoid bone destruction demonstrates extension pattern.
Report Sentence
Aggressive osteolytic/osteoblastic/mixed bone destruction is observed in the __ sinus with disruption of cortical bone integrity; the bone destruction pattern is consistent with metastatic disease.
On MRI, sinonasal metastasis shows variable signal on T2-weighted sequences, and signal characteristics vary depending on the primary tumor. RCC metastases usually show hyperintense T2 signal (high glycogen and lipid content of clear cell carcinoma) and intense enhancement — flow voids may also be seen (hypervascular). Melanoma metastases may show low T2 signal depending on melanin content (paramagnetic melanin effect). Breast and lung metastases show heterogeneous intermediate T2 signal. Necrosis and hemorrhage areas contribute to T2 signal heterogeneity. Tumor infiltration of bone marrow appears as hyperintense signal on T2 STIR — differentiation from bone marrow edema may be difficult.
Report Sentence
A heterogeneous mass with __ signal intensity on T2-weighted sequences is observed in the sinus; signal characteristics are consistent with metastasis originating from the known __ primary tumor.
On DWI, sinonasal metastases generally show diffusion restriction — but the degree of restriction varies with primary tumor and cellularity. Highly cellular tumors (small cell carcinoma metastasis, melanoma) show marked diffusion restriction and low ADC (0.6-0.9 × 10⁻³ mm²/s). RCC metastases may show complex DWI signal due to IVIM effect from hypervascular structure — should be distinguished from true diffusion restriction. No diffusion restriction in necrotic areas (high ADC). DWI is also used for treatment response monitoring and postoperative recurrence evaluation.
Report Sentence
The mass demonstrates diffusion restriction on DWI (ADC: ~__ × 10⁻³ mm²/s); this finding is consistent with cellular tumoral infiltration.
FDG PET-CT shows high sensitivity in sinonasal metastases with generally high SUVmax values. The primary role of PET-CT is staging — detecting synchronous metastases in other organs, identifying the primary tumor (if unknown), and evaluating treatment response. RCC metastases may show variable FDG uptake — low-grade clear cell carcinoma may show low FDG uptake and give false negative results. Melanoma metastases usually show very intense FDG uptake. Lung and breast metastases show moderate-to-high FDG uptake. In postoperative follow-up, PET-CT can detect recurrence and residual disease earlier than anatomic imaging.
Report Sentence
Increased FDG uptake (SUVmax: __) is observed in the sinus mass on FDG PET-CT with __ synchronous metastatic foci detected; findings are consistent with metastatic disease.
Criteria
Most common primary source of sinonasal metastases (40%). Clear cell type most common subtype. Hypervascular — very intense enhancement. Presentation with massive epistaxis. Hematogenous spread via Batson venous plexus.
Distinct Features
Intense enhancement mimicking JNA (but JNA in adolescent male, RCC metastasis in older adult). Flow voids may be seen on MRI. Preoperative embolization mandatory (bleeding control). Osteolytic bone destruction. Primary tumor sometimes discovered after sinonasal metastasis.
Criteria
Second most common primary source. Especially in women. Osteolytic or mixed (osteolytic-osteoblastic) bone destruction. Moderate heterogeneous enhancement. Usually a component of widespread metastatic disease.
Distinct Features
Mixed bone destruction pattern (osteolytic and osteoblastic areas coexisting). Marked diffusion restriction on DWI. Long latent period — may appear years after primary breast cancer treatment. Hormonal receptor status affects treatment planning.
Criteria
Third most common primary source. Both small cell and non-small cell. Predominantly osteolytic bone destruction. Moderate-prominent heterogeneous enhancement. Usually in advanced stage disease. Accompanies widespread metastases.
Distinct Features
Aggressive osteolytic destruction. Necrosis and cavitation may occur. PET-CT plays critical role in staging. Generally poor prognosis — palliative treatment. Chest CT mandatory if primary tumor unknown.
Distinguishing Feature
Primary SCC develops without known malignancy history and usually originates from a single sinus. Metastasis develops with known primary malignancy + hematogenous/lymphatic spread. RCC metastasis shows much more intense enhancement than SCC. Histopathology is the definitive differentiator — SCC shows keratinized squamous epithelium, metastasis reflects primary tumor histology.
Distinguishing Feature
JNA is specific to adolescent males and originates from the sphenopalatine foramen (Holman-Miller sign). RCC metastasis occurs in older adults with known malignancy history. Both show intense enhancement but clinical context (age, gender, known malignancy) is distinguishing. JNA shows bone remodeling, metastasis shows aggressive bone destruction.
Distinguishing Feature
Primary sinonasal melanoma originates from sinonasal mucosa and shows T1 hyperintense, T2 hypointense signal due to melanin. Melanoma metastasis may show the same signal characteristics but known cutaneous or ocular melanoma history is critical for distinction. Superficial mucosal lesion in primary sinonasal melanoma, bone destruction may be dominant in metastasis.
Distinguishing Feature
Adenoid cystic carcinoma is a primary sinonasal tumor and its perineural spread is distinguishing — linear enhancement along trigeminal nerve branches (V2, V3). Metastasis usually does not show perineural spread. Slow growth and late distant metastasis in adenoid cystic carcinoma vs rapid growth and known primary malignancy in sinonasal metastasis are distinguishing.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
Depends on primary tumor type and overall disease burden. Cross-sectional imaging (CT/MRI) every 3 months during treatment, PET-CT for systemic response assessment. Palliative in most cases. RCC sinonasal metastasis: preoperative embolization + surgical excision may provide local control and improve quality of life.When sinonasal metastasis is detected, identification of primary tumor and systemic staging are critical. Biopsy is needed to confirm diagnosis and determine primary tumor histology — however, preoperative embolization should be planned due to hypervascularity if RCC metastasis is suspected. Treatment is generally palliative — systemic chemotherapy/immunotherapy + local radiotherapy. Surgery may be performed for symptom control (epistaxis, nasal obstruction, pain) and local disease control. Sunitinib/pazopanib (TKI) and nivolumab/ipilimumab (immunotherapy) are systemic treatment options for RCC metastasis. Isolated sinonasal metastasis (rare) carries better prognosis and long-term control may be possible with aggressive surgery + radiotherapy.
Sinonasal metastasis is associated with poor prognosis and usually indicates disseminated disease. Metastasis should be considered when a sinonasal mass is detected in patients with known malignancy. Treatment is palliative with radiotherapy and/or surgery.